BioArctic AB (publ)

Stockholm Stock Exchange:BIOA-B.ST

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Sweden

Market Cap

USD 1.73 B

Share Price

USD 19.52

Avg Daily Volume

313,392

Change (1 day)

-1.88%

Change (1 year)

-4.20%

Change (YTD)

8.37%

BioArctic AB (publ) EBITDA Margin for the year ending December 31, 2024: -64.17%

BioArctic AB (publ) EBITDA Margin is -64.17% for the year ending December 31, 2024, a -233.85% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

BioArctic AB (publ) EBITDA Margin for the year ending December 31, 2023 was 47.94%, a 2,495.76% change year over year.
BioArctic AB (publ) EBITDA Margin for the year ending December 31, 2022 was 1.85%, a -100.34% change year over year.
BioArctic AB (publ) EBITDA Margin for the year ending December 31, 2021 was -546.19%, a 356.60% change year over year.
BioArctic AB (publ) EBITDA Margin for the year ending December 31, 2020 was -119.62%, a -373.22% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA Margin	Net Income Margin	EBT Margin	Operating Income Margin

Stockholm Stock Exchange: BIOA-B.ST

BioArctic AB (publ)

CEO	Dr. Gunilla Osswald Ph.D.
IPO Date	Oct. 12, 2017
Location	Sweden
Headquarters	Warfvinges vag 35
Employees	107
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.